Anti Inflammatory News and Research

RSS

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Virginia Commonwealth University receives $1.8M grant to study biology of allergic disease

The National Institutes of Health has awarded Virginia Commonwealth University a grant totaling $1.8 million to study the biology of allergic disease - work which may one day point researchers to the development of therapies to fight asthma, allergy and inflammatory conditions such as rheumatoid arthritis, multiple sclerosis and heart disease.

18 Jul 2013

Magnets could be used for directing stem cells, may help treat heart and vascular diseases

Magnets could be a tool for directing stem cells' healing powers to treat conditions such as heart disease or vascular disease.

17 Jul 2013

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to scientific advancements in analgesia, announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for lower dose submicron indomethacin, a non-steroidal anti-inflammatory drug, for the proposed indication of treatment of mild to moderate acute pain in adults.

16 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

Linda Watkins, Ph.D., Distinguished Professor, Department of Psychology & Neuroscience and Center for Neuroscience, University of Colorado, Co-Chair, Advisory Board, Xalud Therapeutics, Inc. will present research on activating Glial Cells as part of the speaking faculty at the 7th Annual Pain Therapeutics Summit East in Boston, MA.

11 Jul 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the publication of pre-clinical data for VB-201 in the journal of Atherosclerosis.

8 Jul 2013

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Imaging techniques in cancer medicine provide far more than merely information on the scale and location of cancerous ulcers. There are modern methods that additionally characterise the tumour cells precisely, for instance by specific molecules they carry on their surface. Such additional information gives doctors key clues as to the precise cancer type and enables them to predict the probability that a patient will respond to a particular form of therapy.

6 Jul 2013

Seattle researchers map critical molecules that regulate inflammation during flu infection

The influenza virus' ability to mutate quickly has produced new, emerging strains that make drug discovery more critical than ever. For the first time, researchers at Seattle BioMed, along with collaborators at the University of California, San Diego School of Medicine, St. Jude Children's Research Hospital and the University of Washington, have mapped how critical molecules regulate both the induction and resolution of inflammation during flu infection.

6 Jul 2013

New study could lead to better and more targeted drugs for arthritis and cancer

The increased risk of heart attack or stroke associated with many arthritis drugs may be avoidable, according to a new international study co-authored by researchers at Imperial College London.

5 Jul 2013

Salsalate lowers blood glucose and improves glycemic control in T2D, say scientists

Joslin scientists report that salsalate, a drug used to treat arthritis, lowers blood glucose and improves glycemic control in type 2 diabetes. These findings, which were published today by the Annals of Internal Medicine, provide additional evidence that salsalate may be an effective drug to treat type 2 diabetes.

3 Jul 2013

Curcumin may provide lasting protection against lung damage in premature infants

Turmeric, a key ingredient in spicy curry dishes, has long been known to have medicinal values. Now new research finds a substance in turmeric, curcumin, may provide lasting protection against potentially deadly lung damage in premature infants.

3 Jul 2013

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.

2 Jul 2013

$Higher levels of Omega-3 fatty acids may reduce risk for hip fractures in postmenopausal women$

Higher levels of Omega-3 fatty acids may reduce risk for hip fractures in postmenopausal women

Higher levels of omega-3 fatty acids in the blood may reduce the risk for hip fractures in postmenopausal women, recent research suggests.

28 Jun 2013

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.

28 Jun 2013

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.

28 Jun 2013

Supreme Court sides with generic drug makers

The Supreme Court ruled on Monday that generic drugmakers cannot be sued under state law for adverse reactions to their products, a decision that consumer advocates called a blow to patient safety. In a 5-4 vote, the court ruled for Mutual Pharmaceutical Co, owned by Sun Pharmaceutical Industries Ltd, overturning a multimillion-dollar jury award to a badly injured patient in New Hampshire who alleged a generic drug she had taken was unsafe based on its chemical design (Hurley and Berkrot, 6/24).

26 Jun 2013

Primary care physicians prefer to prescribe NSAIDS for chronic pain, report shows

For treating the estimated 100 million Americans with chronic pain -- a population larger than those with heart disease, cancer and diabetes combined -- researched reported in The Journal of Pain shows that primary care physicians overwhelmingly prefer to prescribe non-steroidal anti-inflammatory medications, in accordance with published clinical practice guidelines.

26 Jun 2013

Study finds U-shaped association between consumption of fish and risk of developing AF

Moderation seems to be key when it comes to eating fish to prevent atrial fibrillation according to an observational study presented at the EHRA EUROPACE congress held 23 to 26 June in Athens, Greece.

25 Jun 2013

Anti Inflammatory News and Research

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Virginia Commonwealth University receives $1.8M grant to study biology of allergic disease

Magnets could be used for directing stem cells, may help treat heart and vascular diseases

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

Soligenix announces personalized medicine collaboration with SciClone

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Seattle researchers map critical molecules that regulate inflammation during flu infection

New study could lead to better and more targeted drugs for arthritis and cancer

Salsalate lowers blood glucose and improves glycemic control in T2D, say scientists

Curcumin may provide lasting protection against lung damage in premature infants

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Higher levels of Omega-3 fatty acids may reduce risk for hip fractures in postmenopausal women

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Janssen receives complete response letter from FDA for XARELTO sNDA

Supreme Court sides with generic drug makers

Primary care physicians prefer to prescribe NSAIDS for chronic pain, report shows

Study finds U-shaped association between consumption of fish and risk of developing AF

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News